Achilles Therapeutics (NASDAQ:ACHL - Get Free Report) is expected to issue its quarterly earnings data before the market opens on Thursday, April 3rd. Analysts expect Achilles Therapeutics to post earnings of ($0.36) per share for the quarter.
Achilles Therapeutics Stock Performance
Shares of ACHL remained flat at $1.48 during midday trading on Friday. Achilles Therapeutics has a twelve month low of $0.63 and a twelve month high of $1.51. The firm has a market cap of $60.83 million, a PE ratio of -0.90 and a beta of 1.25. The stock's 50-day moving average is $1.35 and its two-hundred day moving average is $1.14.
About Achilles Therapeutics
(
Get Free Report)
Achilles Therapeutics plc, a biopharmaceutical company, develops precision T cell therapies to treat solid tumors. Its platform identifies mutations formed early in the development of cancer. The company offers PELEUS, a proprietary AI-powered bioinformatics platform, used to identify clonal neoantigens in a patient.
Recommended Stories
Before you consider Achilles Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Achilles Therapeutics wasn't on the list.
While Achilles Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
